Training dogs to differentiate Pseudomonas aeruginosa from other cystic fibrosis bacterial pathogens: not to be sniffed at?

The major cause of lung damage in cystic fibrosis (CF) is infection with bacterial pathogens, the most prevalent of which is Pseudomonas aeruginosa, chronically infecting ~60% patients by adolescence/adulthood (www.cysticfibrosis.org.uk/news/registry-report-2017). P. aeruginosa may be successfully eradicated, but frequently recurs and establishes biofilms resistant to antibiotics/host defences [1]. Chronic P. aeruginosa is closely linked with pulmonary exacerbation frequency, faster lung function decline and earlier mortality [2]. The huge antibiotic burden imposed upon patients and the resulting bacterial resistance, allergies and toxicities compound the detrimental impact of the infection itself. Chronic P. aeruginosa should be avoided if at all possible; early detection and rapid treatment may be crucial in achieving this.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Original Articles: Research letters Source Type: research

Related Links:

CONCLUSION: Our results did not show that S. aureus found in nasal mucosa membrane is significantly different in patients with or without NP. However, association of the presence of S. aureus in patients with nasal polyposis with asthma, allergy and inflammation has been shown. PMID: 31785225 [PubMed - as supplied by publisher]
Source: Neuroendocrinology Letters - Category: Endocrinology Tags: Neuro Endocrinol Lett Source Type: research
Usually B is perceived as a purely neutrophilic disease. However, eosinophilic type of inflammation is observed in pts with B in clinical practice. The aim of the study was to determine the correlation between blood eosinophils level and sensitization to Aspergillus fumigatus (AF).Methods: The study included cohort of pts with confirmed by HRCT B. Peripheral blood eosinophils were counted in stable phase. Total serum IgE was evaluated by using conventional electrochemiluminescence immunoassay (ECLIA) and specific IgE to AF was measured by immunoCAP technology. The methods of descriptive statistics and non-parametric statis...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Allergy and immunology Source Type: research
In this study, OVA-sensitized/challenged mice were treated with AZM after inoculation with RSV. We found that AZM treatment not only suppressed AHR, but also reduced all key markers of exacerbation. Furthermore, TNFa-produced by alveolar macrophages was reduced with AZM treatment. Recombinant TNFa administration could reverse exacerbation in the presence of AZM. Our findings highlight the mechanism of AZM suppressed AHR and airway inflammation in RSV-induced asthma exacerbation through targeting the innate immune response linked to alveolar macrophages and TNFa production.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Allergy and immunology Source Type: research
Conclusions. The applied diagnostic criteria had no significant effect on the reported rate of ABPA prevalence. PMID: 31702121 [PubMed - as supplied by publisher]
Source: European Annals of Allergy and Clinical Immunology - Category: Allergy & Immunology Tags: Eur Ann Allergy Clin Immunol Source Type: research
Inhaled and oral glutathione may benefit lung function in patients with cystic fibrosis (CF), although vitamin and mineral antioxidant supplementation does not appear to have a positive treatment effect, an updated Cochrane Review reveals.Reuters Health Information
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Pulmonary Medicine News Source Type: news
We present a 23-year-old male with a history of cystic fibrosis (CF) with associated renal disease, bronchiectasis, pneumothorax, and distal intestinal obstruction syndrome admitted for CF exacerbation. Sputum culture was positive for methicillin resistant Staphylococcus aureus (MRSA). Chest imaging revealed extensive opacities in the left lung. His FEV1 during admission was 52% (baseline 70%). Allergy was consulted as inhaled vancomycin therapy was preferred, but the patient had previous vancomycin-induced reactions.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Source Type: research
High antibiotic utilization is an essential element of life-saving care for cystic fibrosis (CF) patients. However, adverse drug reactions (ADRs) to antibiotics occur more commonly and discrete types of ADRs may differ in CF patients compared to the general population. Characterization of documented ADRs among CF patients is needed in order understand how antibiotic utilization can be improved for CF patients.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Source Type: research
Allergic bronchopulmonary aspergillosis (ABPA) affects up to 15% of patients with cystic fibrosis (CF), representing a significant clinical challenge. It is especially a concern in the pediatric population given adverse effects of steroids in this population. Here we report on the use of omalizumab in the treatment of steroid-resistant ABPA in a pediatric patient with CF.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Source Type: research
Reactions were much more common in patients with cystic fibrosis and those with previously identified environmental or drug allergies.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Allergy & Clinical Immunology News Source Type: news
BackgroundChronic rhinosinusitis (CRS) is associated with bronchiectasis; however, this relationship has not been well studied in the United States (US) population. In this work we aimed to determine the prevalence of CRS among patients with bronchiectasis affiliated with a US tertiary medical center and identify which comorbid diseases are associated with the presence of CRS in patients with bronchiectasis.MethodsThis was a retrospective cohort study in which data were obtained from a large database warehouse at a tertiary care center. Patients with bronchiectasis were identified from 2007 to 2017 using diagnosis codes fr...
Source: International Forum of Allergy and Rhinology - Category: Allergy & Immunology Authors: Tags: ORIGINAL ARTICLE Source Type: research
More News: Allergy | Allergy & Immunology | Cystic Fibrosis | Respiratory Medicine | Toxicology | Training | Universities & Medical Training